Unibest

Pharmaceutical intermediates

Danicopan Intermediates

4 pharmaceutical intermediates for Danicopan. Indication: Adult Paroxysmal Nocturnal Hemoglobinuria (PNH).

提交项目All intermediates

About Danicopan

Originator
Achillion Pharmaceuticals Inc
Indication
Adult Paroxysmal Nocturnal Hemoglobinuria (PNH)
Approved Date
03/29/2024
NCE Patent
03/29/2029
DS/DP
02/25/2035

Available intermediates

4 intermediates currently listed for Danicopan. Request specifications, documentation or a quotation for any item below.

Danicopan intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
(2S,4R)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid203866-14-2//
1-(5-Bromo-1H-indazol-3-yl)ethan-1-one886363-74-2//
(2S,4R)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide1903745-21-0//
2-MethylpyriMidine-5-boronic Acid Pinacol Ester1052686-67-5//

Other programs under D

Dabigatran EtexilateDabigatran etexilate mesylateDabrafenib MesylateDacomitinibDapagliflozinDaridorexant HydrochlorideDarolutamideDasatinib Hydrate

Building toward Danicopan?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →